Design and rationale for RE-VERSE AD: A phase 3 study of idarucizumab, a specific reversal agent for dabigatran
| Image |  |
|---|---|
| Description | scientific article published on 28 May 2015 |
| Author/s | |
| Publication date | May 28, 2015 |
| Language | |
| Country of origin | |
| Wikipedia link | |
| Copyright status | |
| Missing/wrong data? | Edit Wikidata item |